Wuhan University
武汉大学
Hospitals that carry this university's name, added together, plus papers and trials that name only the university.
Research activity, not treatment quality. Not medical advice. How this works
Nasopharyngeal carcinoma
鼻咽癌Led 27 of 2,375 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (23.4%).
- Open trials led
- 0
- Research papers it led
- 27
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.8%
Over half of these papers are lab or animal studies.
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Fluoroscopy-Guided Balloon Dilation for Severe Nasopharyngeal Stenosis Resulting from Radiotherapy for Nasopharyngeal Carcinoma.
- Predicting prognosis of nasopharyngeal carcinoma based on deep learning: peritumoral region should be valued.
- Deep Learning for Predicting Distant Metastasis in Patients with Nasopharyngeal Carcinoma Based on Pre-Radiotherapy Magnetic Resonance Imaging.
- Deep learning for locally advanced nasopharyngeal carcinoma prognostication based on pre- and post-treatment MRI.
- Homing Effect Directed Cuprous Delivery Activates Cuproptosis Against Nasopharyngeal Carcinoma and Metastasis.
Trials on ClinicalTrials.gov6
- QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.
- A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
- Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial
- A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor
- Immune Score Based Radiomics in Nasopharyngeal Carcinoma
- PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients
Oesophageal squamous cell carcinoma
食管鳞状细胞癌Led 15 of 2,923 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (6.9%).
- Open trials led
- 2
- Research papers it led
- 15
- Trials it led
- 3
- Share of China's trials
- 0.5%
- Share of the world's papers
- 0.3%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Evaluation of Concurrent Chemoradiotherapy for Survival Outcomes in Patients With Synchronous Oligometastatic Esophageal Squamous Cell Carcinoma.
- Efficacy and Safety of Second-Line Immune Checkpoint Inhibitor Rechallenge in Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Retrospective Study.
- Radiotherapy plus camrelizumab and irinotecan for oligometastatic esophageal squamous cell carcinoma patients after first-line immunotherapy plus chemotherapy failure: An open-label, single-arm, phase II trial.
- Survival impact of concurrent chemoradiotherapy for elderly patients with synchronous oligometastatic esophageal squamous cell carcinoma: A propensity score matching and landmark analyses.
- Porphyromonas gingivalis extracellular vesicles promotes tumor metastasis in esophageal squamous cell carcinoma by inducing PRKACB/JNK/ NFATC2 axis.
Trials on ClinicalTrials.gov5
- A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophageal Squamous Cell Carcinoma
- Influence Mechanism of Tumor Microenvironment Changes on Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma
- The Value of Sintilimab Consolidation Therapy After Definitive Concurrent Chemoradiotherapy for Locally Advanced Thoracic Esophageal Cancer
- Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.
- Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
Hepatocellular carcinoma
肝细胞癌Led 194 of 14,765 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (5.5%).
- Open trials led
- 0
- Research papers it led
- 194
- Trials it led
- 8
- Share of China's trials
- 0.5%
- Share of the world's papers
- 0.7%
Over half of these papers are lab or animal studies.
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- A genome-wide siRNA screen identifies previously unknown proviral and antiviral host factors in HBV infection.
- Decreased propionyl-CoA metabolism facilitates metabolic reprogramming and promotes hepatocellular carcinoma.
- METTL5 stabilizes c-Myc by facilitating USP5 translation to reprogram glucose metabolism and promote hepatocellular carcinoma progression.
- Clinical performance evaluation of a plasma dual-target methylation test for the detection of primary liver cancer: a multicenter study.
- Splenic volume as a predictor of survival in cancer patients treated with immune checkpoint inhibitors.
Trials on ClinicalTrials.gov6
- Clinical Study for Combined Analysis of CTC and Exosomes on Predicting the Efficacy of Immunotherapy in Patients With Hepatocellular Carcinoma
- Surufatinib Alone or Combined With Anti-PD-1 mAb in the Treatment of Advanced Hepatocellular Carcinoma
- Single-cell RNA Sequencing Resolves the Regulatory Role of HBV on the Hepatocellular Carcinoma Immune Microenvironment
- Umbilical Cord Blood Derived MAK Immune Cells Combined With Standard Second-Line Treatments for Hepatobiliary and Pancreatic Malignancies
- Clinical Study of MAK Immune Cells in the Treatment of PHC
- Circulating Tumor Cell Capture for Early Diagnosis and Postoperative Tumor Recurrence Monitoring of Liver Cancer
Stomach cancer
胃癌Led 104 of 9,782 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (3.9%).
- Open trials led
- 3
- Research papers it led
- 104
- Trials it led
- 12
- Share of China's trials
- 0.8%
- Share of the world's papers
- 0.5%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Effect of a deep learning-based system on the miss rate of gastric neoplasms during upper gastrointestinal endoscopy: a single-centre, tandem, randomised controlled trial.
- Evaluation of the effects of an artificial intelligence system on endoscopy quality and preliminary testing of its performance in detecting early gastric cancer: a randomized controlled trial.
- Artificial intelligence assistance narrows the experience gap in endoscopic reporting of gastric lesions: a prospective clinical trial.
- Efficacy of endoscopic therapy in patients with T1b gastric cancer and construction of a prognostic prediction model: a retrospective cohort study and multicenter validation study.
- SIRT1 Expression in Human Gastrointestinal Tumors and Its Clinical Significance.
Trials on ClinicalTrials.gov6
- A Real-World Study of Neoadjuvant/Conversion Therapy for Locally Advanced or Metastatic Gastric Cancer
- A Real-world Research on the Prevention and Treatment of Peritoneal Metastasis and Malignant Ascites by Intraperitoneal Infusion of rmhTNF in Gastric and Colorectal Malignant Tumors
- Samples Procurement for Colorectal Cancer, Gastric Cancer, and Non-malignant Disease
- Multimodal AI for Predicting Response to Neoadjuvant Immunotherapy in Gastric Cancer (PRISM-GC)
- First-line Apatinib Combined With Tislelizumab and Chemotherapy for Advanced GC
- Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Locally Advanced Gastric Cancer
Retinoblastoma
视网膜母细胞瘤Led 8 of 301 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (12.0%).
- Open trials led
- 0
- Research papers it led
- 8
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.7%
Over half of these papers are lab or animal studies.
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- The Results of Pars Plana Vitrectomy in the Treatment of Intraocular Retinoblastoma: A Retrospective Study and Literature Review.
- Comprehensive analysis of single-cell and bulk RNA sequencing uncover tumor microenvironment diversity in invasive Retinoblastoma.
- Highly Efficient Photodynamic Therapy with Mitochondria-Targeting Aggregation-Induced Emission Photosensitizer for Retinoblastoma.
- GSDME Increases Chemotherapeutic Drug Sensitivity by Inducing Pyroptosis in Retinoblastoma Cells.
- mTOR inhibition by TAK-228 is effective against growth, survival and angiogenesis in preclinical retinoblastoma models.
Osteosarcoma
骨肉瘤Led 52 of 2,257 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (4.3%).
- Open trials led
- 0
- Research papers it led
- 52
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 1.0%
Over half of these papers are lab or animal studies.
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Efficacy and safety of regorafenib in the treatment of bone sarcomas: systematic review and meta-analysis.
- Metastatic dedifferentiated liposarcoma of the mediastinum with osteosarcomatous differentiation: A case report.
- Mandibular rhabdomyosarcoma with TFCP2 rearrangement and osteogenic differentiation: a case misdiagnosed as fibrous dysplasia or low-grade central osteosarcoma.
- Incidental detection of Ewing sarcoma in the thoracic spinal cord by 18F-FDG PET/CT in a pediatric patient with cerebral infarction.
- Trimerization-Enhanced NIR-II/Photoacoustic Nanoprobes for Precision Osteosarcoma Imaging.
Gastrointestinal stromal tumour
胃肠道间质瘤Led 3 of 523 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (6.3%).
- Open trials led
- 0
- Research papers it led
- 3
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.2%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led3
- Survival trends of gastrointestinal stromal tumor in real-world settings: a population-based retrospective study.
- Ki-67 labelling index is related to the risk classification and prognosis of gastrointestinal stromal tumours: a retrospective study.
- The development of a prediction model based on deep learning for prognosis prediction of gastrointestinal stromal tumor: a SEER-based study.
Trials on ClinicalTrials.gov1
Neuroblastoma
神经母细胞瘤Led 17 of 1,132 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (8.8%).
- Open trials led
- 0
- Research papers it led
- 17
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.4%
Over half of these papers are lab or animal studies.
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- L116 Deletion in CSPα Promotes α-Synuclein Aggregation and Neurodegeneration.
- PERK inhibition mitigates acrylamide-induced tau phosphorylation and synaptic deficits via the GSK-3β and ATF4 pathways in human neuroblastoma SH-SY5Y cells.
- Neuronal-specific TNFAIP1 ablation attenuates postoperative cognitive dysfunction via targeting SNAP25 for K48-linked ubiquitination.
- Neuro-Inspired Biomimetic Microreactor for Sensory Recovery and Hair Follicle Neogenesis under Skin Burns.
- SNAP25 ameliorates postoperative cognitive dysfunction by facilitating PINK1-dependent mitophagy and impeding caspase-3/GSDME-dependent pyroptosis.
Ewing sarcoma
尤文肉瘤Led 2 of 163 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (8.6%).
- Open trials led
- 0
- Research papers it led
- 2
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.2%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Multiple myeloma
多发性骨髓瘤Led 12 of 1,676 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (4.8%).
- Open trials led
- 3
- Research papers it led
- 12
- Trials it led
- 6
- Share of China's trials
- 1.2%
- Share of the world's papers
- 0.1%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Clinical and immunological characteristics of high-risk double-hit multiple myeloma.
- Chemotherapy plus therapeutic plasmapheresis with 4% human albumin solution in multiple myeloma patients with acute kidney injury: a prospective, open-label, proof-of-concept study.
- Comparison of clinical characteristics, treatment efficacy and survival in patients with newly diagnosed multiple myeloma with single- versus multi-site extramedullary invasion.
- Extracellular Volume Fraction Based on Cardiac Magnetic Resonance T1 Mapping: An Effective Way to Evaluate Cardiac Injury Caused by Cardiac Amyloidosis in Patients with Multiple Myeloma.
- Analysis of Risk Factors of Coagulation Dysfunction and Hemorrhage in Newly Diagnosed Hyperleukocytic Acute Myeloma Leukemia.
Trials on ClinicalTrials.gov6
- Randomised Controlled Trial of Artificial Intelligence-assisted Health Education
- Helical Tomotherapy in Multiple Myeloma
- AI-Based Fine Morphological Subtyping of Myeloma Single Cells for Predicting FISH Abnormalities
- A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- A Phase Ib/II Clinical Study on the Application of Linperlisib Combined with the VRD Regimen in Newly Diagnosed Patients with Multiple Myeloma
- Double Filtration Plasmapheresis Combined With Chemotherapy
Aplastic anaemia
再生障碍性贫血Led 3 of 412 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (17.2%).
- Open trials led
- 0
- Research papers it led
- 3
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.2%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led3
- Exosomes derived from mesenchymal stem cells regulate Treg/Th17 balance in aplastic anemia by transferring miR-23a-3p.
- 53BP1 regulates p53-E2F7-dependent transcriptional gene repression and participates in the Fanconi anemia pathway.
- The Compromised Fanconi Anemia Pathway in Prelamin A-Expressing Cells Contributes to Replication Stress-Induced Genomic Instability.
Fanconi anaemia
范可尼贫血Led 2 of 68 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (8.8%).
- Open trials led
- 0
- Research papers it led
- 2
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.5%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Myasthenia gravis
重症肌无力Led 1 of 499 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (6.6%).
- Open trials led
- 0
- Research papers it led
- 1
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.04%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Trials on ClinicalTrials.gov4
- A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
- A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis
- Study of Telitacicept in Generalized Myasthenia Gravis
- A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis
Moyamoya disease
烟雾病Led 13 of 356 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (19.9%).
- Open trials led
- 0
- Research papers it led
- 13
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 1.1%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Treatment strategies and prognostic analysis of moyamoya disease associated with single intracranial aneurysm.
- Role of scalp arteries in revascularization after side to side anastomosis in moyamoya disease patients.
- Association of retrograde bypass flow depth along cortical recipient arteries with revascularization outcomes in direct bypass surgery for Moyamoya disease.
- Treatment of moyamoya disease with intracranial aneurysm by surgical clipping combined with encephalo-duro-myo-synangiosis surgery: a case report and literature review.
- Increase in age at onset of moyamoya disease in China over 25 years.
Anti-NMDA receptor encephalitis
抗 NMDA 受体脑炎Led 3 of 264 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (10.2%).
- Open trials led
- 0
- Research papers it led
- 3
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.4%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led3
- Successful sequential treatment with ofatumumab followed by efgartigimod for refractory autoimmune encephalitis with dual anti-NMDAR and anti-GFAP antibody positivity: first case report.
- An adolescent patient with anti-N-methyl-D-aspartate receptor encephalitis with motor aphasia as the first symptom and complicated by peripheral nerve damage: A case report and literature review.
- Case Report: Efficacy of ofatumumab in refractory anti-NMDAR encephalitis: case series and literature review.
Idiopathic pulmonary fibrosis
特发性肺纤维化Led 7 of 989 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (4.3%).
- Open trials led
- 0
- Research papers it led
- 7
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.2%
Over half of these papers are lab or animal studies.
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Enhanced THBS2 promotes collagen synthesis and inflammatory secretome of fibroblasts in idiopathic pulmonary fibrosis.
- Blocking ATF4 attenuates pulmonary fibrosis by preventing lung fibroblast activation and macrophage M2 program.
- The role of inflammatory factors in mediating the causal effects of type 1 diabetes mellitus on idiopathic pulmonary fibrosis: A two-step Mendelian randomization study.
- Human epididymis protein 4-annexin II binding promotes aberrant epithelial-fibroblast crosstalk in pulmonary fibrosis.
- Plasma LTBP2 as a potential biomarker in differential diagnosis of connective tissue disease-associated interstitial lung disease and idiopathic pulmonary fibrosis: a pilot study.
Trials on ClinicalTrials.gov3
- Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
- A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
Amyotrophic lateral sclerosis
肌萎缩侧索硬化症Led 7 of 779 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (8.3%).
- Open trials led
- 0
- Research papers it led
- 7
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.1%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Pain characteristics in amyotrophic lateral sclerosis patients and its impact on quality of life: a prospective observational study in a northern city of China.
- Amyloid fibril structures and ferroptosis activation induced by ALS-causing SOD1 mutations.
- MicroRNA-23a-3p Is Upregulated in Plasma Exosomes of Bulbar-onset ALS Patients and Targets ERBB4.
- C9orf72 regulates the unfolded protein response and stress granule formation by interacting with eIF2α.
- Cryo-EM structure of an amyloid fibril formed by full-length human SOD1 reveals its conformational conversion.
Behçet disease
白塞病Led 4 of 245 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (22.9%).
- Open trials led
- 0
- Research papers it led
- 4
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.3%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led4
- Intestinal vascular diseases misdiagnosed as Crohn disease: analysis of 13 cases.
- Candidate Drugs Screening for Behcet's Disease Based on Bioinformatics Analysis and Mouse Experiments.
- Retinal microvasculature features in patients with Behcet's disease: a systematic review and meta-analysis.
- A huge intramyocardial cystic-like dissection with left ventricle outflow tract obstruction in Behcet's heart disease.
IgA nephropathy
IgA 肾病Led 4 of 736 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (9.4%).
- Open trials led
- 0
- Research papers it led
- 4
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.2%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led4
- Telitacicept plus low-dose mycophenolate mofetil in the treatment of IgA nephropathy: a retrospective study.
- Hyperuricemia and hypertriglyceridemia indicate tubular atrophy/interstitial fibrosis in patients with IgA nephropathy and membranous nephropathy.
- Causality between Celiac disease and kidney disease: A Mendelian Randomization Study.
- Potential benefits and related treatment effects of calcineurin inhibitors combined with steroid for IgA nephropathy: a systematic review and meta-analysis.
Trials on ClinicalTrials.gov3
Familial adenomatous polyposis
家族性腺瘤性息肉病Led 2 of 59 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (10.2%).
- Open trials led
- 0
- Research papers it led
- 2
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.3%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Leber hereditary optic neuropathy
Leber 遗传性视神经病变Led 2 of 52 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (21.1%).
- Open trials led
- 0
- Research papers it led
- 2
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.6%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.